Pliant Therapeutics Inc (PLRX)

Form 8-K - Current report

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095Oral presentation at...

Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a...

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors

SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (Nasdaq: PLRX) today...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report